Previous close | 2.4400 |
Open | 2.4900 |
Bid | 2.2000 x 36200 |
Ask | 2.2400 x 2900 |
Day's range | 2.0801 - 2.5750 |
52-week range | 1.6700 - 18.6800 |
Volume | |
Avg. volume | 1,346,180 |
Market cap | 153.981M |
Beta (5Y monthly) | -1.02 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.1140 |
Earnings date | 10 Aug 2022 - 15 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 16.43 |
SHORT HILLS, N.J., June 16, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced it entered into an agreement with PCI Pharma Services (PCI), a leading integrated global contract development manufacturing organization (CDMO), to provide importation, release and commercialization services in the United Kingdom (UK) for lenzilumab. Under the agreement,
SHORT HILLS, N.J., June 03, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced today that representatives will present and participate at multiple investors conferences in June 2022. Details of the conferences are as follows:
SHORT HILLS, N.J., May 24, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced that Cameron Durrant, Chairman & CEO, will give a corporate presentation at 11:00am EDT today at the H.C. Wainwright Global Investment Conference taking place in Miami, FL, May 23-26, 2022. In his presentation Dr. Durrant will provide an update on progress towards release of top